TeamedOn International, Inc. is dedicated to advancing gene therapies specifically targeting rare ocular diseases, with a primary focus on inherited retinal disorders (IRDs). The company is committed to developing innovative treatments that address significant unmet medical needs in the field of ophthalmology. With a rich history of over 30 years in gene therapy research, TeamedOn is leveraging the advancements made in this area, including the notable approval of Luxturna, the first gene therapy for IRDs by the US FDA. This therapy utilizes an adeno-associated viral vector to deliver the RPE65 gene, showcasing the potential of gene therapy in restoring vision for patients suffering from various retinal conditions.

In addition to its internal research and development efforts, TeamedOn is actively seeking partnerships for collaboration and co-development to enhance its pipeline of gene therapies. The company aims to tackle a range of ocular diseases, including those that have shown promising results in clinical trials, such as choroideremia and X-linked retinitis pigmentosa. However, challenges remain, as certain conditions like X-linked retinoschisis and Stargardt disease have not yet demonstrated significant improvements in clinical studies. TeamedOn's overarching goal is to restore sight and prevent vision loss for patients globally, positioning itself as a key player in the evolving landscape of gene therapy for ocular diseases.

United States

TEAMEDON INTERNATIONAL, LLC is a company based out of 10134 TREBLE CT, ROCKVILLE, Maryland, United States.

TeamedOn

Company Details